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Abstract 
Background: 
Rodent studies of bone in chronic kidney disease have primarily relied on end-point 
examinations of bone microarchitecture. This study used longitudinal in vivo microcomputed 
tomography (in vivo µCT) to characterize the onset and progression of bone loss, specifically 
cortical porosity, in the Cy/+ rat of model of CKD.  
Methods: 
Male CKD rats and normal littermates were studied. In vivo µCT scans of the right distal tibia 
repeated at 25, 30, and 35 weeks were analyzed for longitudinal changes in cortical and 
trabecular bone morphometry. In vitro µCT scans of the tibia and femur identified spatial 
patterns of bone loss across distal, midshaft and proximal sites.  
Results: 
CKD animals had reduced BV/TV and cortical BV at all time points but developed cortical 
porosity and thinning between 30 and 35 weeks. Cortical pore formation was localized near the 
endosteal surface. The severity of bone loss was variable across bone sites, but the distal tibia 
was representative of both cortical and trabecular changes. 
Conclusions:  
The distal tibia was found to be a sensitive suitable site for longitudinal imaging of both cortical 
and trabecular bone changes in the CKD rat. CKD trabecular bone loss progressed through ~30 
weeks followed by a sudden acceleration in cortical bone catabolism. These changes varied in 
timing and severity across individuals, and cortical bone loss and porosity progressed rapidly 
once initiated. The inclusion of longitudinal µCT in future studies will be important for both 
reducing the number of required animals and to track individual responses to treatment. 
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1. Introduction
Renal osteodystrophy in chronic kidney disease (CKD) patients is marked by significant
bone changes including reduced bone quality, trabecular bone loss, increased cortical porosity, 
cortical thinning, and increased fragility.(1-4) Cortical porosity and thinning are unique features 
of high-turnover renal osteodystrophy compared to osteoporosis, and their detection and 
treatment are of special interest due to their undesirable effects on fracture risk.(5-8)  
The gold standard for identifying a patient’s subtype of renal osteodystrophy is transiliac 
bone biopsy, but patients are not always suited or willing to undergo the invasive 
procedure.(9,10) Histomorphometry analysis of the biopsy requires specialized expertise, and 
the method only provides a snapshot of bone turnover at a single time and location. Serum or 
urine biomarkers may provide clues to a patient’s mineral metabolism over time, but studies to 
date have shown limited predictive relationships between currently used biomarkers and 
fracture risk in CKD patients.(11) In contrast, imaging approaches, such as DXA and peripheral 
quantitative computed tomography (pQCT), can identify patients with decreased bone mass, 
discriminate CKD patients with and without fracture, and monitor treatment effects 
longitudinally.(1,2,12-14) High resolution-pQCT (HR-pQCT) produces 3D images of the distal 
radius and tibia at a resolution sufficient to distinguish changes in the trabecular and cortical 
bone compartments.(3,14) This feature provides useful insight into bone status in CKD patients, 
whose bone loss patterns often include more cortical thinning and porosity than in patients with 
osteoporosis.(2,14,15) The effective single-scan radiation dose from HR-pQCT is quite low 
(~3µSv), but patients’ cumulative exposure from all sources should be considered, especially 
when repeated imaging is planned.(16,17) Barriers to widespread clinical use of HR-pQCT 
include the limited availability of instruments and the need for greater standardization.(16,18) 
Pre-clinical researchers rely primarily on end-point measures to assess CKD bone disease 
and treatment effects. Paralleling the advancement of HR-pQCT for clinical use, the 
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development and increasing availability of in vivo µCT has made it possible to longitudinally 
track bone microarchitecture in live animals.(19-23) Successful applications of the technique in 
rats to monitor bone morphometry include models of ovariectomy(24,25), limb unloading(26), 
and drug treatment.(27) Rodent studies of chronic kidney disease to date have primarily relied 
on end-point examinations of bone microarchitecture.(28-35) These terminal examinations 
present challenges for differentiating bone changes pre-dating treatment from those occurring 
after treatment onset, potentially limiting the detection or interpretation of preventative versus 
restorative drug effects. A longitudinal study design in which measurements are taken non-
invasively on the same individual and the same location over time has the potential to overcome 
this barrier by comparing changes to the individual’s pre-treatment baseline. The clinical 
features of CKD-MBD with secondary hyperparathyroidism are recapitulated by the Cy/+ rat 
model of CKD.(28,36,37) The goal of the present study was to use longitudinal in vivo 
microcomputed tomography (in vivo µCT) to characterize the onset and progression of bone 
loss, specifically cortical porosity, in the Cy/+ rat of model of CKD.  
2. Methods 
2.1 Animal model and experimental design 
Male Han:SPRD rats heterozygous for the Anks6 R823W mutation (Cy/+) were 
characterized by the presence of azotemia at 10 weeks of age as in our previous 
studies.(28,36,37) Normal littermates (NL) were used as matched controls. All animals were 
individually housed on a standard 12hr light cycle. In order to promote CKD progression in Cy/+ 
animals, all animals were switched from standard chow to a casein diet (Purina AIN-76A; 0.7% 
Pi, 0.6% Ca) at 24 weeks of age.(36) Bodyweights were measured weekly from 25-35 weeks of 
age.  Animals were euthanized by CO2 inhalation at 35 weeks. Blood biochemistry and bone 
morphometry were measured longitudinally from 25 to 35 weeks as described below. Consistent 
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with survival rates in our previous studies, three CKD animals died suddenly or required 
humane euthanasia between 32-34 weeks of age; these animals were excluded from analysis 
and replaced to achieve the final group sizes (18 NL and 13 CKD). All animal procedures 
received approval from the Institutional Animal Care and Use Committee prior to initiating the 
studies. 
2.2 Blood Biochemistry 
Approximately 400ul of blood was collected from the tail vasculature of each animal at 25, 
30, and 35 weeks of age. Blood plasma was tested for BUN, calcium, and phosphorus using 
colorimetric assays (Point Scientific, Canton, MI, USA, or Sigma kits). Intact PTH was 
determined by ELISA (Alpco, Salem, NH, USA) at 35 weeks for a subset of animals (N=6-
7/group). 
2.3 Microcomputed tomography 
2.3.1 Longitudinal Scans – Distal Tibia 
All scans were performed on a Bruker Skyscan 1176 in vivo µCT system at a 9µm resolution 
(0.5mm Al filter, 60kV, 417µA, 0.9º rotation step, 180º scanning, 926ms exposure). Each scan 
lasted ~10 minutes. The average NL rat girth in this study was too large to position the animals’ 
torsos within the scanner bore; this limited the potential sites of interest to the lower extremities. 
Because of this the distal tibia was chosen as the site of interest. For in vivo scans at 25 and 30 
weeks, animals were anesthetized with isofluorane and placed supine on the instrument bed. 
The right hind limb was extended with the foot and ankle placed through a polystyrene foam 
positioning ring firmly taped to the bed. Dental wax was molded around the foot to hold the leg 
in place. Tape was used to secure the tail, left hind limb, and adjacent soft tissues within the 
scanner bed but out of the field of interest. This approach ensured the distal tibia was isolated in 
the field of view and consistently immobilized. 
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The 35-week longitudinal scans were performed after death to reduce the number of animal 
procedures. Right hind limbs were harvested at the hip immediately after sacrifice with all soft 
tissues intact, wrapped in saline-soaked gauze, and stored frozen. Limbs were thawed at room 
temperature on the day of scanning, positioned, and scanned under conditions otherwise 
identical to those used for in vivo scans. Exposed muscle around the proximal femur was 
wrapped in Parafilm to maintain hydration during the scan. The limb was immobilized on the 
instrument bed using the same positioning ring, wax, and orientation as used with live animals, 
and identical scan parameters were used. 
2.3.2 In vitro Scans – Whole Tibia and Femur 
Immediately following the 35-week longitudinal scan, the right tibia and femur were isolated, 
cleaned of all soft tissue, wrapped in Parafilm with a few drops of saline to maintain hydration, 
and scanned. The removal of soft tissue required a slightly lower voltage to maintain proper 
scan exposure, but the remaining parameters matched the longitudinal scans (0.5mm Al filter, 
55kV, 417µA, 0.9º rotation step,180º scanning, 926ms exposure).  
2.3.3 Scan summary 
The studied groups (18 NL and 13 CKD animals) were part of a larger interventional 
experiment that started a few weeks before the in vivo µCT system became available due to 
logistical issues. As a result, a subset of the 31 animals have incomplete longitudinal datasets.  
The missing data were addressed during statistical analysis by the use of mixed models, which, 
unlike standard linear models or ANOVA, can evaluate incomplete repeated measures data 
without the use of replacement values or the complete exclusion of subjects with missing 
values. Overall, the dataset includes complete 25, 30, and 35-week scans from 17 animals (8 
NL and 9 CKD). The raw files for one 30-week CKD scan were lost due to a software error 
during imaging, resulting in this animal having data for 25 and 35 weeks. Ten animals (8 NL and 
2 CKD) missed the baseline 25-week scan but were scanned at 30 and 35 weeks, and 3 
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animals (2 NL and 1 CKD) were scanned only at 35 weeks. 35-week longitudinal and traditional 
in vitro scans were analyzed for all 31 animals (18 NL and 13 CKD). 
2.4 Analysis 
Following reconstruction, longitudinal scans of the distal tibia were 3D-registered and 
analyzed using manufacturer-suppled software (SkyScan DataViewer and CTan). Baseline (25 
week) scans were rotated to a standardized orientation, and 3D registration of successive scans 
(30 to 25 weeks, 35 to 30 weeks) maximized consistency in the location and volume of bone 
analyzed for each time point (Figure 1a). A 1 mm volume of interest (VOI) centered 4 mm distal 
of the tibia-fibula junction was drawn to isolate the cortex and analyzed for cortical geometry 
and porosity (Figure 1b). A second 1mm VOI was drawn for distal trabecular bone analysis 
beginning 3mm proximal of the tibia inferior articular surface.  
In vitro scans of the isolated and cleaned tibiae and femora were rotated to a standardized 
orientation and analyzed for cortical geometry and porosity at 3 sites (proximal, midshaft and 
distal) located at 20%, 50%, and 80% of the bone’s length (Figure 1b). VOI locations were 
chosen as a percentage of bone length to standardize for potential bone length differences. 
Although this was not possible for the longitudinal scans spanning the distal tibia (tibia lengths 
were not measured at 25 or 30 weeks), the longitudinal and in vitro distal tibia VOI were 
comparable in location and size (Figure 1b). Proximal tibia trabecular bone morphology was 
analyzed for a 1mm-long VOI beginning 1mm distal of the proximal growth plate.  Distal femur 
trabecular bone morphology was analyzed for a 1mm-long VOI beginning 2.5mm proximal of 
the distal growth plate. 
2.5 Statistics 
Statistical analyses were performed in R (version 3.5.1). Linear mixed model analysis using 
lme4 (R package version 1.1-17) was used for repeated measures to allow the inclusion of 
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samples with missing data.(38) The fitted mixed models included a random intercept for subject 
and factors for phenotype, time, and their interaction. In the case of end-point microCT 
measures quantified at multiple bone sites, time was replaced by site in the model specification. 
Significant factor effects were identified using p-values calculated using lmerTest (R package 
version 3.0-1).(39) Post hoc pairwise comparisons across phenotype and time (or site) with 
multiple comparison adjustment using Tukey’s method were used to identify specific group and 
timepoint (or site) differences for significant factor effects (emmeans, R package version 
1.2.3).(40) Mann-Whitney nonparametric tests were used to test the significance of phenotype 
for single time or site measures. Spearman correlations were used to test for relationships 
between biochemistry and bone measures. Biochemistry correlations were performed within 
each phenotype for all successful blood collections/analyses across the three time points. The 
resulting sample sizes for correlation assessment were: 6-7 for PTH, 23-26 for phosphorus and 
calcium, and 29-36 for BUN. All statistical tests were 2-tailed. Data is presented as mean + SD. 
3. Results 
3.1 Bodyweight and Biochemistries 
CKD and NL animals had similar bodyweights up to ~32 weeks of age at which point they 
diverged with NL being higher than CKD (Figure 2a). Biochemistry results (Fig 2b-e) were 
typical for this Cy/+ model. Plasma BUN was elevated in CKD animals at 25 weeks compared to 
NL and continued to increase through 35 weeks. Consistent with prior studies, calcium was not 
significantly different between NL and CKD animals at 35 weeks, but CKD animals had 
significantly higher phosphorous and PTH levels.  
3.2 Longitudinal µCT 
Areas of bone loss and gain over the 10-week study were observed in superimposed 2D 
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slices from the registered longitudinal scans (Figure 3). The selected color scheme in the 
overlays (bottom row) highlights changes between the overlaid time points, with areas of bone 
loss appearing darker and areas of new bone lighter. These images from a representative CKD 
animal illustrate that bone loss was primarily trabecular between 25 and 30 weeks. Cortical 
bone losses were more significant between 30 and 35 weeks, and the full extent of bone 
resorption over the 10-week study is seen in the overlaid 25 and 35-week longitudinal scans. 
Registered cutaway 3D renderings also visualized the degree and patterns of bone loss (Fig 4). 
We consistently observed that the cortical porosity formation in CKD bones was first visible near 
the endocortical surface. Significant pore enlargement eventually eroded the original endosteal 
surface, resulting in thinning of the cortex and expansion of the marrow cavity. 
The timing and patterns of CKD bone loss were further explored by quantitative analysis of 
the registered VOIs (Figure 5). NL animals maintained trabecular BV/TV (Fig 5a) and gained 
cortical volume (Fig 5e) and thickness (Fig 5f) at the distal tibia over the 10-week study. Both NL 
and CKD animals had slightly increased mean trabecular thickness over time, but in the case of 
CKD animals this was likely due to the loss of the thinnest trabeculae as evidenced by the 
combination of reduced BV/TV (Fig 5a), reduction in Tb.N (Fig 5d) and increase in spacing (Fig 
5c). Compared to NL, CKD animals also had reduced cortical volume at 25, 30 and 35 weeks 
(Fig 5e). Trabecular BV/TV continued to decrease in CKD animals over time and was 
significantly lower at 30 and 35 weeks compared to baseline. In contrast, cortical volume slightly 
increased in CKD from 25 to 30 weeks and maintained the increase from baseline at 35 weeks. 
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Despite the relative gains in cortical volume, CKD cortical thickness did not increase as in 
NL animals and was significantly less than NL at 35 weeks. Cortical porosity (Fig 5d) did not 
change in NL animals and was significantly elevated in CKD at 35 weeks compared to both 
earlier timepoints. Cross-sectional thickness (Fig 5e), a 2D cortical parameter calculated as 
Ct.Cs.Th = 2/(Bone Surface/Bone Volume), was more greatly reduced than cortical thickness in 
CKD animals compared to NL at 35 weeks, presumably due to its sensitivity to both bone 
volume loss and increasing bone surface resulting from pore formation. A scatterplot with 
LOESS curve fit (Fig 5f) shows the biphasic relationship between trabecular BV/TV and cross-
sectional thickness measured for each animal at 25, 30, and 35 weeks. Notably, cross-sectional 
thickness was only reduced when BV/TV was below a threshold of approximately 20%. 
Together, these data illustrate that trabecular bone loss largely preceded cortical porosity and 
thinning in the CKD distal tibia between 25 and 35 weeks.  
3.3 In vitro µCT  
In vitro scans of the 35-week tibia and femur revealed spatial variability in the cortical bone 
changes in CKD animals. Figure 6d shows 3D renderings of the tibia and femur from 
representative NL (left panel) and CKD (right panel) animals. Cortical volume was reduced in 
CKD bones at all measured sites except the distal femur, where there was no significant 
difference in cortical BV compared to NL (Fig 6a).  Cross-sectional thickness (Fig 6c) similarly 
detected significant reductions from CKD at all but the distal femur site, but the effect was 
consistently stronger than for cortical volume. The degree of cortical porosity (Fig 6b) was highly 
variable for the CKD animals. Although porosity was visible in CKD animals at all sites during 
analysis, the increase compared to NL animals only reached statistical significance in a subset 
of the measured sites in the repeated site analysis: the midshaft tibia, midshaft femur, and distal 
femur. The increased distal tibia porosity in CKD animals did reach statistical significance in the 
longitudinal statistical analysis (Fig 5), and that difference is attributable to the longitudinal 
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analysis’ reduced number of post hoc multiple comparisons and greater power from repeated 
measures of the same bone over time.  
Trabecular bone volume fraction was significantly reduced in CKD animals at the distal tibia 
site used for longitudinal measures.  Trabecular BV/TV was also reduced at the distal femur but 
not statistically affected by CKD at the proximal tibia site. Spearman correlations between 
BV/TV at the distal tibia and the proximal tibia and distal femur sites confirmed significant 
relationships between BV/TV measures across the trabecular sites (Fig 7). 
3.4 Correlations between bone measures and biochemistry 
Significant correlations were identified between longitudinal bone measures, including 
cortical porosity and cross-sectional thickness, and corresponding levels of BUN, phosphorus, 
and PTH (Fig 8). No significant correlations were found with calcium level.   
4. Discussion 
This study identified a variable but rapid acceleration of cortical bone loss in the CKD rat 
within a 5-week period between 30 and 35 weeks of age. In prior studies without baseline 
measures, animals with significantly greater bone loss at study completion might have had more 
severe disease, greater bone loss, and porosity formation preceding the onset of study 
treatments.(28-30,41,42) The current results reveal that the high variability in bone endpoint 
measurements, particularly at 30 weeks, is attributable to variability in the timing of a sudden 
escalation in bone loss after 30 weeks of age. Previous terminal studies established the most 
significant development of mineral and bone problems in male CKD rats fed a casein diet 
occurs sometime after 25 weeks of age.(36) Evidence of cortical and cancellous bone loss in 
CKD rats compared to controls was identified by endpoint measures at both 30 and 35 weeks, 
but increased cortical porosity was only detected at 35 weeks.(28,30) Without baseline or 
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longitudinal measures for these studies, it was unknown whether the lack of cortical porosity at 
30 weeks reflected a pattern of progressive bone loss or was due to variability across 
individuals and/or studies. We have now established that a slow, progressive, largely trabecular 
bone loss continues in the Cy/+ male rat through ~30 weeks of age, at which point there is a 
sudden and impressive acceleration in cortical bone catabolism. Because the timing of this 
acceleration is slightly variable, the method established in this study could feasibly be used in 
future studies to stage individual animals prior to the start an experiment to selectively 
investigate treatments at a specific disease stage.  
The longitudinal scans revealed consistent spatial patterns, with the first signs of cortical 
porosity always localized near, but not visibly touching, the endosteal surface. Porosity 
increased through both pore enlargement and increased number of pores. Superimposed 
registered longitudinal scans revealed eventual erosion of the endosteal surface as a result of 
pore growth. As a result, in the more severe cases, cortical porosity eventually became a less 
sensitive indicator of overall bone loss due to the loss of the original bone envelope and 
resulting reduction in measured cortical total volume. Thus, in characterizing the severity of 
CKD cortical bone disease, it is important to consider cortical porosity within the larger context 
of reduced cortical bone volume and cortical thinning. We found that cross-sectional thickness, 
which effectively normalizes bone area to bone surface, may provide a concise measure for this 
type of cortical bone loss. Further, a trabecular BV/TV approaching a critical threshold (~20% at 
the distal tibia in this study) may identify individuals at risk for developing significant cortical 
bone loss. On an individual level, registered baseline and longitudinal imaging is an effective 
means to track and identify loss of the original bone envelope in addition to changes in cortical 
porosity. 
We found significant correlations between BUN, phosphorus, and PTH levels and measures 
of bone loss in the CKD animals which indicated greater bone loss in animals with greater 
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disturbances in blood biochemistry. This was to be expected given the progressive nature of this 
CKD model, with noted features of the disease increasing in parallel. It should be noted, 
however, that the strong covariance between the biochemical measures precludes any 
conclusions about specific cause and effect relationships based on our results. Although a 
strong relationship was found between PTH and bone loss, these correlations must be 
interpreted cautiously because measurement of PTH was limited to 35 weeks and a small 
number of individuals (6-7/group). In a previous study, elevated PTH levels at 25 weeks in male 
Cy/+ rats continued to increase at 30 weeks and again through 35 weeks.(29) Given the known 
metabolic effects of hyperparathyroidism on bone, the sudden onset of catabolism of cortical 
bone in this study may potentially be explained by progressively increasing PTH levels 
eventually reaching a critical threshold. Cortical bone loss has been shown to be fully prevented 
in this model by calcium treatment to control the secondary hyperparathyroidism.(28) It has not 
been established whether the cortical porosity and thinning can be reversed once established, 
but the longitudinal µCT approach reported here makes such a study possible. 
This study performed longitudinal in vivo µCT measures on the rat distal tibia. The distal site 
was chosen for its minimal soft tissue mass, the ability to isolate the site within the x-ray field, 
and the size limitations of the instrument. These restrictions parallel those for clinical HR-pQCT, 
which is limited to the distal tibia and radius, adding to this study’s clinical significance. Given 
the potential limitations of making conclusions about a systemic problem based on a single site, 
it was of interest to determine whether bone parameters of the distal tibia are reflective of other 
bone sites. Furthermore, prior studies of the Cy/+ rat have focused on the proximal, rather than 
distal, tibia. The in vitro scans of the full tibiae and femora allowed us to address these 
questions. We found the bone measures at the distal site paralleled those at the proximal tibia, 
with both sites showing similar degrees of cortical bone volume loss, reduced cross-sectional 
thickness, and cortical porosity at 35 weeks. Trabecular BV/TV at the distal tibia was 
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significantly reduced in CKD animals and more affected than trabecular BV/TV at the proximal 
site. Trabecular bone volume fraction at the distal tibia was greater than, but correlated with, 
BV/TV at the distal femur and proximal tibia sites. However, despite this congruity across the 
tibia and femur sites at study end, it is possible that these (or other) bone sites are affected 
differently over the course of CKD progression. 
One limitation of this work, and longitudinal µCT studies as a whole, is the potential radiation 
impact on the animal, tissues, and measures of interest. Unfortunately, we did not perform end-
point µCT on the contralateral limb, so we are unable to determine with certainty whether the 
repeated radiation exposures directly to the limb significantly impaired bone morphology or 
interacted with the effects of CKD. Qualitatively, we noted no discernable pattern when 
comparing the endpoint bone parameters of animals who received all three scans compared to 
those that did not. It is important to note that in this study the radiation exposure was limited to 
the distal tibia site, yet the patterns of CKD bone loss at study-end were largely consistent 
across the femur and tibia as evaluated by whole-bone in vitro scans, as well as with bones 
from our previous work that did not involve in vivo CT. Though we cannot rule out the possibility 
of systemic radiation effects in this study, our data are not suggestive that this drove the major 
outcomes of this work.  
In conclusion, the distal tibia was found to be a sensitive and suitable site for in vivo 
longitudinal imaging of both cortical and trabecular bone changes in the CKD rat. These 
changes varied in timing and severity across individuals, and cortical bone loss and porosity 
progressed rapidly once initiated. Although the reported details of cortical porosity formation are 
specific to the studied Cy/+ rat model, the ability to observe cortical porosity progress with this 
approach should be possible in other animal models. The inclusion of longitudinal µCT in future 
studies will be important for both reducing the number of required animals and to track individual 
responses to treatment.  
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Figure 1 - (a) An example orthographic view of 3D-registered 25 and 30-week scans of the 
distal tibia in a CKD animal. Inverse color scales for each of the scans (inset) were chosen so 
that areas of bone loss and formation are highlighted as dark and light, respectively, in the over-
laid views. (b) 1mm Cortical VOI locations are shown for longitudinal and in vitro scans.  
 
 
Figure 2 - a) CKD animals weighed less beginning at 32 weeks. Blood BUN (b), phosphorus (d) 
and PTH (e) became increasingly elevated in CKD animals. Calcium levels (c) were significantly 
higher than NL at 25 but not 35 weeks. Bar plots show mean +/- SD as well as individual data 
points.  *p <= 0.05; **p <= 0.01; ***p <= 0.001; ****p <= 0.0001 
 
 
Figure 3 - Registered scans (top row) from a representative CKD animal illustrate the large 
cortical porosity formation (+) observed between 30 and 35 weeks. Trabecular bone loss (*) was 
present by 30 weeks, Over-lays of 25 and 30, 30 and 35, and 25 and 35 weeks (bottom row) 
highlight the locations and timing of bone loss, with dark and light regions identifying areas of 
removed and added bone, respectively.  
 
 
Figure 4- 3D renderings of longitudinal tibia scans for a NL and a CKD animal. (a) Registered 
cross-sectional views are shown along with corresponding values of trabecular BV/TV (%) and 
cortical porosity (%) for the bones shown. CKD trabecular bone loss preceded cortical porosity 
formation. (b) Cut views of the cortical VOI for the same CKD animal demonstrate the endosteal 
clustering and first appearance of cortical porosity at 35 weeks. 
 
 
Figure 5 - Longitudinal measures of trabecular and cortical bone volume at the distal tibia. CKD 
animals had increasing reductions in trabecular bone volume fraction (a) driven by a reduction 
in trabecular number (d) and increased spacing (c). Cortical volume (e), cortical thickness (f), 
and cortical cross-sectional thickness (h) were increasingly reduced compared to NL over the 
10-week study. CKD levels of cortical porosity (g) were only increased at 35 weeks. A 
scatterplot with LOESS curve fit (i) shows the nonlinear biphasic relationship between trabecular 
BV/TV and cross-sectional thickness measured for each animal at 25, 30 and 35 weeks; 
Ct.Cs.Th is reduced below a Tb.BV/TV threshold of ~20%. Bar plots show mean +/- SD.  
Cortical porosity is shown with a box and whisker plot and log axis to accommodate the strongly 
skewed distribution. *p <= 0.05; **p <= 0.01; ***p <= 0.001; ****p <= 0.0001 
 
 
Figure 6 - In vitro 35-week measures of cortical bone at proximal, midshaft and distal sites for 
the femur and tibia showed variable effects of CKD by location. Cortical volume (a) and cortical 
cross-sectional thickness (c) were reduced in CKD at all sites except the distal femur. Cortical 
porosity (b) was quite variable in CKD animals and significantly increased at the tibia midshaft, 
femur midshaft, and distal femur in this analysis. Panel (d) presents rendered volumes of the ex 
vivo tibia and femur scans from the same NL and CKD animals as shown in Figure 4. Bar plots 
show mean +/- SD.  Cortical porosity is shown with a box and whisker plot and log () axis to 
accommodate the strongly skewed distribution. *p <= 0.05; **p <= 0.01; ***p <= 0.001; ****p <= 
0.0001 
 
Figure 7 - Trabecular bone volume at the proximal tibia, distal tibia, and distal femur sites. CKD 
animals had significantly reduced BV/TV (a) compared to NL at both distal locations. Spearman 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
  20 
correlations confirmed significant relationships between the distal tibia BV/TV and BV/TV at both 
the proximal tibia (b) and distal femur (c), supporting the usefulness of the distal tibia for 
monitoring BV/TV changes in CKD over time. Bar plots show mean +/- SD. *p <= 0.05; **p <= 
0.01; ***p <= 0.001; ****p <= 0.0001 
 
Figure 8 - Relationships between blood biochemistry and cortical porosity (a-d) or cortical cross-
sectional thickness (e-h) as tested by Spearman correlation for NL and CKD animals. Data 
include all longitudinal time points collected for each measure. BUN ( a,e), Phosphorus (b,f), 
and PTH (d,h) were significantly associated with cortical porosity (+) and cross-sectional 
thickness (-) in CKD animals. Calcium (c,g) was not associated with either bone measure in 
CKD animals. No significant relationships were identified between the blood and bone 
measures for NL animals. N= 6-36 for the various correlations, see methods for more details.   
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Highlights 
 The distal tibia is a sensitive site for longitudinal µCT of cortical and trabecular bone 
changes in the CKD rat. 
 CKD trabecular bone loss largely precedes the initial formation of cortical porosity. 
 CKD cortical porosity formation is initially concentrated near the endosteal surface. 
 CKD cortical bone loss varies in timing and severity across individuals but porosity 
progresses rapidly once initiated.  
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